评估葡萄糖代谢异常性小纤维神经病变中的角膜树突状细胞。
Assessing corneal dendritic cells in glucose dysregulation small-fibre neuropathy.
作者信息
Idiaquez Juan Francisco, Barnett-Tapia Carolina, Perkins Bruce A, Bril Vera
机构信息
Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Division of Neurology, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada.
Division of Endocrinology and Metabolism, University of Toronto, and the Leadership Sinai Centre for Diabetes, Sinai Health, Toronto, Canada.
出版信息
J Peripher Nerv Syst. 2024 Dec;29(4):400-405. doi: 10.1111/jns.12671. Epub 2024 Nov 12.
BACKGROUND AND AIMS
Small-fibre neuropathy (SFN) is associated with glucose dysregulation, including impaired glucose tolerance (IGT) and type 2 diabetes (T2D). Corneal confocal microscopy (CCM) offers a non-invasive tool to assess corneal nerve damage and dendritic cell density (DCD). In this study, we investigated corneal DCD in patients with SFN and glucose dysregulation, defined as IGT or T2D.
METHODS
We enrolled 38 patients with SFN + glucose dysregulation, 51 with SFN + non-glucose dysregulation and 20 healthy controls. All participants underwent neurological examination, neurophysiology and CCM.
RESULTS
Individuals with SFN and glucose dysregulation had higher DCD compared with healthy controls (p = .01), and mature DCD was higher in IGT SFN patients than in T2D patients.
INTERPRETATION
Higher DCD in IGT compared with controls and patients with established T2D may suggest that DCD is a biomarker of early neuropathy.
背景与目的
小纤维神经病变（SFN）与葡萄糖调节异常有关，包括糖耐量受损（IGT）和2型糖尿病（T2D）。角膜共焦显微镜检查（CCM）提供了一种非侵入性工具，用于评估角膜神经损伤和树突状细胞密度（DCD）。在本研究中，我们调查了SFN合并葡萄糖调节异常（定义为IGT或T2D）患者的角膜DCD。
方法
我们纳入了38例SFN合并葡萄糖调节异常患者、51例SFN合并非葡萄糖调节异常患者和20名健康对照者。所有参与者均接受了神经学检查、神经生理学检查和CCM检查。
结果
与健康对照者相比，SFN合并葡萄糖调节异常的个体DCD更高（p = 0.01），且IGT SFN患者的成熟DCD高于T2D患者。
解读
与对照组和已确诊T2D的患者相比，IGT患者的DCD更高，这可能表明DCD是早期神经病变的生物标志物。
Zotero 插件